South Bend, Indiana – A groundbreaking neurobiology study has delivered the first direct scientific comparison of the two dominant laboratory models used to study multiple sclerosis (MS), potentially reshaping how future treatments are developed.
Published by researchers at University of Notre Dame, the study examined how two widely used experimental systems — cuprizone (CPZ) and lysophosphatidylcholine (LPC) — mimic the destruction and repair of myelin, the protective fatty sheath that insulates nerve fibers in the brain and spinal cord.
The findings challenge a long-standing assumption in MS research: that the two models are largely interchangeable.
Instead, the researchers discovered that each model produces dramatically different cellular and genetic responses, meaning the choice of model could directly influence whether a potential therapy succeeds or fails before ever reaching human trials.
A Disease of Broken Neural Insulation
Multiple sclerosis affects more than one million Americans and millions more worldwide. The disease occurs when the immune system mistakenly attacks myelin, the insulating material wrapped around nerve fibers much like plastic coating surrounds electrical wiring.
As myelin deteriorates, electrical communication throughout the nervous system becomes disrupted, leading to symptoms ranging from fatigue and muscle spasms to numbness, pain, and vision loss.
Over time, damaged regions known as lesions accumulate in the brain and spinal cord, contributing to progressive neurological decline.
Because obtaining live tissue samples from patients with advanced MS is extraordinarily difficult, researchers depend heavily on animal and preclinical models to study how myelin is destroyed — and whether it can be regenerated.
Until now, however, scientists lacked definitive evidence about which model best reflects the biology of human disease.
CPZ and LPC: Similar Outcome, Different Biology
The two most common laboratory models for demyelination research are CPZ and LPC.
Both ultimately strip away myelin, but they do so in very different ways.
CPZ induces widespread myelin loss gradually over several weeks, creating a slow-burning degeneration across large brain regions. LPC, by contrast, creates a rapid, sharply localized lesion within days.
That distinction turns out to matter enormously.
According to lead researcher Katrina Adams, the slower CPZ model is particularly valuable for studying oligodendrocytes — the specialized cells responsible for producing myelin.
“If you’re studying the myelin-producing cells and what’s happening to them in MS — are they stressed, dying or trying to repair? — CPZ is better, since the loss of myelin is more gradual,” Adams explained.
LPC, however, generates a much more aggressive immune response, making it more suitable for studying inflammatory and autoimmune reactions.
“For studying the immune cells that respond to the myelin loss, LPC may be better, since the immune response is more aggressive than in CPZ,” Adams said.
The findings provide researchers with what Adams described as a “road map” for selecting the most biologically relevant system depending on the therapeutic target under investigation.
Mapping Disease Cell by Cell
One of the study’s most important advances came through the use of single-cell RNA sequencing, a cutting-edge technique that allows scientists to analyze gene activity in individual cells.
Using this approach, the team constructed detailed genetic maps of lesions produced by both CPZ and LPC and directly compared them with real human MS tissue samples.
That comparison allowed researchers to identify which cellular and genetic patterns truly mirror human disease.
“By matching each model to features seen in diseased tissue from real patients, we can be sure that we’re targeting things that are actually causing disease in human patients,” Adams said.
The researchers were surprised to discover major differences in gene expression between the two models, even within similar cell types.
Some of these genetic shifts may promote myelin repair, while others may interfere with regeneration — a question the team plans to investigate further.
Why Current MS Treatments Still Fall Short
Modern MS therapies primarily focus on suppressing the immune system to reduce flare-ups and prevent additional damage.
While these drugs can slow disease progression, they do not repair the myelin already lost inside existing lesions.
That missing capability — true remyelination — remains one of the biggest unmet goals in neurology.
The Notre Dame study may help move the field closer to that objective by clarifying which experimental models are best suited for studying nerve repair itself rather than simply controlling inflammation.
“The strategic use of these two preclinical models is essential for translating insights into therapies that might restore lost myelin,” Adams said.
“We need to better understand the very process of demyelination in order to treat one of the root causes of this debilitating disorder.”
A Turning Point for MS Drug Discovery
The implications extend far beyond academic debate.
Choosing the wrong preclinical model can send drug development down biologically irrelevant pathways, wasting years of effort and potentially obscuring treatments that might otherwise work in humans.
By directly linking laboratory models to real patient tissue at the genetic level, the study offers researchers a clearer blueprint for designing therapies that target the mechanisms actually driving disease.
For a field still searching for ways to regenerate damaged nervous tissue, that precision could prove transformative.
As scientists push beyond immune suppression toward actual neural repair, this work may mark a crucial turning point in the long quest to reverse the damage caused by multiple sclerosis.
Original Research: Open access.
“A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions” by Erin L. Aboelnour, Veronica R. Vanoverbeke, Elizabeth A. Maupin, Madelyn M. Hatfield & Katrina L. Adams. Nature Communications
DOI:10.1038/s41467-026-72383-y
Contact
Brandi Wampler – University of Notre Dame
Associate Director of Media Relations
Phone: +1 574-631-8183
Email: [email protected]